# CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

> clinical trial · VERIFIED · 2026-08-25

Status: RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: Acute Myeloid Leukemia With Gene Mutations

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04493164

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.